Literature DB >> 26031404

Human Induced Pluripotent Stem Cell-Derived Microvesicles Transmit RNAs and Proteins to Recipient Mature Heart Cells Modulating Cell Fate and Behavior.

Sylwia Bobis-Wozowicz1, Katarzyna Kmiotek1, Malgorzata Sekula1,2, Sylwia Kedracka-Krok3, Elzbieta Kamycka1, Marta Adamiak1, Urszula Jankowska3,2, Anna Madetko-Talowska4, Michal Sarna5,2, Miroslaw Bik-Multanowski6, Jacek Kolcz5, Dariusz Boruczkowski7, Zbigniew Madeja1, Buddhadeb Dawn8, Ewa K Zuba-Surma1.   

Abstract

Microvesicles (MVs) are membrane-enclosed cytoplasmic fragments released by normal and activated cells that have been described as important mediators of cell-to-cell communication. Although the ability of human induced pluripotent stem cells (hiPSCs) to participate in tissue repair is being increasingly recognized, the use of hiPSC-derived MVs (hiPSC-MVs) in this regard remains unknown. Accordingly, we investigated the ability of hiPSC-MVs to transfer bioactive molecules including mRNA, microRNA (miRNA), and proteins to mature target cells such as cardiac mesenchymal stromal cells (cMSCs), and we next analyzed effects of hiPSC-MVs on fate and behavior of such target cells. The results show that hiPSC-MVs derived from integration-free hiPSCs cultured under serum-free and feeder-free conditions are rich in mRNA, miRNA, and proteins originated from parent cells; however, the levels of expression vary between donor cells and MVs. Importantly, we found that transfer of hiPSC components by hiPSC-MVs impacted on transcriptome and proteomic profiles of target cells as well as exerted proliferative and protective effects on cMSCs, and enhanced their cardiac and endothelial differentiation potential. hiPSC-MVs also transferred exogenous transcripts from genetically modified hiPSCs that opens new perspectives for future strategies to enhance MV content. We conclude that hiPSC-MVs are effective vehicles for transferring iPSC attributes to adult somatic cells, and hiPSC-MV-mediated horizontal transfer of RNAs and proteins to injured tissues may be used for therapeutic tissue repair. In this study, for the first time, we propose a new concept of use of hiPSCs as a source of safe acellular bioactive derivatives for tissue regeneration. © AlphaMed Press.

Entities:  

Keywords:  Cell signaling; Induced pluripotent stem cells; Microvesicles; Paracrine activity; Tissue regeneration

Mesh:

Substances:

Year:  2015        PMID: 26031404     DOI: 10.1002/stem.2078

Source DB:  PubMed          Journal:  Stem Cells        ISSN: 1066-5099            Impact factor:   6.277


  37 in total

Review 1.  Pathogenic roles of microvesicles in diabetic retinopathy.

Authors:  Wei Zhang; Song Chen; Ming-Lin Liu
Journal:  Acta Pharmacol Sin       Date:  2017-07-17       Impact factor: 6.150

Review 2.  Exosomes Generated From iPSC-Derivatives: New Direction for Stem Cell Therapy in Human Heart Diseases.

Authors:  Ji-Hye Jung; Xuebin Fu; Phillip C Yang
Journal:  Circ Res       Date:  2017-01-20       Impact factor: 17.367

3.  Acellular therapeutic approach for heart failure: in vitro production of extracellular vesicles from human cardiovascular progenitors.

Authors:  Nadia El Harane; Anaïs Kervadec; Valérie Bellamy; Laetitia Pidial; Hany J Neametalla; Marie-Cécile Perier; Bruna Lima Correa; Léa Thiébault; Nicolas Cagnard; Angéline Duché; Camille Brunaud; Mathilde Lemitre; Jeanne Gauthier; Alexandra T Bourdillon; Marc P Renault; Yeranuhi Hovhannisyan; Solenne Paiva; Alexandre R Colas; Onnik Agbulut; Albert Hagège; Jean-Sébastien Silvestre; Philippe Menasché; Nisa K E Renault
Journal:  Eur Heart J       Date:  2018-05-21       Impact factor: 29.983

Review 4.  Human Pluripotent Stem Cell-Derived Extracellular Vesicles: Characteristics and Applications.

Authors:  Richard Jeske; Julie Bejoy; Mark Marzano; Yan Li
Journal:  Tissue Eng Part B Rev       Date:  2020-01-16       Impact factor: 6.389

Review 5.  Beneficial effects of exosomes secreted by cardiac-derived progenitor cells and other cell types in myocardial ischemia.

Authors:  Lucio Barile; Giuseppina Milano; Giuseppe Vassalli
Journal:  Stem Cell Investig       Date:  2017-11-18

6.  Human mesenchymal stromal cell-derived extracellular vesicles attenuate aortic aneurysm formation and macrophage activation via microRNA-147.

Authors:  Michael Spinosa; Guanyi Lu; Gang Su; Sai Vineela Bontha; Ricardo Gehrau; Morgan D Salmon; Joseph R Smith; Mark L Weiss; Valeria R Mas; Gilbert R Upchurch; Ashish K Sharma
Journal:  FASEB J       Date:  2018-05-29       Impact factor: 5.191

7.  Mesenchymal stem cells-derived exosomes ameliorate blue light stimulation in retinal pigment epithelium cells and retinal laser injury by VEGF-dependent mechanism.

Authors:  Guang-Hui He; Wei Zhang; Ying-Xue Ma; Jing Yang; Li Chen; Jian Song; Song Chen
Journal:  Int J Ophthalmol       Date:  2018-04-18       Impact factor: 1.779

8.  Induced neural progenitor cells abundantly secrete extracellular vesicles and promote the proliferation of neural progenitors via extracellular signal-regulated kinase pathways.

Authors:  Yizhao Ma; Kaizhe Wang; Jiabin Pan; Zhaohuan Fan; Changhai Tian; Xiaobei Deng; Kangmu Ma; Xiaohuan Xia; Yunlong Huang; Jialin C Zheng
Journal:  Neurobiol Dis       Date:  2018-12-04       Impact factor: 5.996

Review 9.  Extracellular Vesicles and the Application of System Biology and Computational Modeling in Cardiac Repair.

Authors:  Venkata Naga Srikanth Garikipati; Farnaz Shoja-Taheri; Michael E Davis; Raj Kishore
Journal:  Circ Res       Date:  2018-07-06       Impact factor: 17.367

10.  Induced Pluripotent Stem Cell (iPSC)-Derived Extracellular Vesicles Are Safer and More Effective for Cardiac Repair Than iPSCs.

Authors:  Marta Adamiak; Guangming Cheng; Sylwia Bobis-Wozowicz; Lin Zhao; Sylwia Kedracka-Krok; Anweshan Samanta; Elzbieta Karnas; Yu-Ting Xuan; Bozena Skupien-Rabian; Xing Chen; Urszula Jankowska; Magdy Girgis; Malgorzata Sekula; Arash Davani; Slawomir Lasota; Robert J Vincent; Michal Sarna; Kathy L Newell; Ou-Li Wang; Nathaniel Dudley; Zbigniew Madeja; Buddhadeb Dawn; Ewa K Zuba-Surma
Journal:  Circ Res       Date:  2017-11-08       Impact factor: 17.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.